NYSE:IBER Ibere Pharmaceuticals (IBER) Stock Price, News & Analysis → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free IBER Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.18▼$10.1850-Day Range$10.15▼$10.2152-Week Range$9.74▼$10.75Volume44,499 shsAverage Volume110,000 shsMarket Capitalization$175.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ibere Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Ibere Pharmaceuticals Stock (NYSE:IBER)Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.Read More Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. IBER Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive IBER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNYSE:IBER CUSIPN/A CIK1835205 Webwww.iberepharma.com Phone267-765-3222FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.01% Return on Assets4.47% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.09 per share Price / Cash Flow112.42 Book Value($0.63) per share Price / Book-16.16Miscellaneous Outstanding Shares17,250,000Free Float13,800,000Market Cap$175.61 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Osagie O. Imasogie Esq. (Age 61)Chairman & CEO Ms. Lisa M. Gray CPA (Age 58)CPA, CVA, CFO, Exec. VP & Director Mr. Zoltan Kerekes J.D. (Age 57)COO, Exec. VP & Director Key CompetitorsARYA Sciences Acquisition Corp IVNASDAQ:ARYDFuture Health ESGNASDAQ:FHLTPrenetics GlobalNASDAQ:PREenGeneNASDAQ:ENGNRegulus TherapeuticsNASDAQ:RGLSView All Competitors This page (NYSE:IBER) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ibere Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.